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W e  report the isolation, characterization, and total 
synthesis of a small peptide ligand for nicotinic acetyl­
choline receptors (nAChRs). It is highly active against 
the neuromuscular receptor in frog but not in mice. In 
contrast, it induces seizures w h e n  injected centrally in 
mice and rats, suggesting that it m a y  target neuronal 
n A C h R s  in mammals. Although such receptors m a y  be 
important in both normal cognition and the pathophysi­
ology of several neuropsychiatric disorders, there are 
few ligands to discriminate between the multiple recep­
tor subtypes.
The n e w  peptide is a highly divergent a-conotoxin 
from the snail Conus imperialis, which preys on 
polychaete worms. In this article, the purification, 
structural analysis, synthesis, and preliminary physi­
ological characterization of a-conotoxin Iml (a-CTx-Iml) 
are reported. The sequence of the peptide is: Gly-Cys- 
Cys-Ser-Asp-Pro-Arg-Cys-Ala-Trp-Arg-Cys-NH2. The pep­
tide shows striking sequence differences from all 
a-conotoxins of fish-hunting Conus, but its disulfide- 
bridging is similar: [2-8; 3-12]. W e  suggest that cone ven­
o m s  m a y  provide an array of ligands with selectivity for 
various neuronal n A C h R  subtypes.
Mammalian nicotinic acetylcholine receptors (nAChRs)1 can 
be divided into two groups: 1) those found in skeletal muscle, 
which have the subunit composition of (a)2p y 8 in developing 
muscle and (a)2fieS in mature muscle; and 2) those found in 
neurons, which are much more diverse and believed to be made 
up of combinations of a (a2-a7) and P ()32-/34) subunits (1). Com­
pared to muscle nAChRs, little is known about the functional 
aspects of neuronal nAChRs. This is in part due to the paucity 
of ligands tha t target specific neuronal subtypes.
Although a number of antagonists for nAChRs have been 
described, most of these, such as neosurugatoxin and lopho- 
toxin, are not subtype-specific and appear to inhibit all neuro­
nal nAChR subtypes tested (2). The only subtype-specific in­
hibitors of nAChRs that have been characterized so far come 
from the venom of the Taiwanese banded krait, B ungarus m ul-
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ticinctus. There is now good evidence that the major cholinergic 
toxin in this venom, a-bungarotoxin, specifically inhibits nico­
tinic receptors tha t contain an a 7-subunit (3).
There is also a minor component of this venom known by 
convention as neuronal bungarotoxin (also known as x-bunga- 
rotoxin, toxin F, or Bgt 3.1), which acts a t a 3/32- and to a lesser 
extent a4P2-containing receptors. This toxin is only available by 
isolation from natural sources and has been difficult to obtain 
in significant quantities with high purity. Indeed, a t the pre­
sent time it is commercially unavailable.
Conus is a large genus of predatory snails tha t feed on fish, 
snails, and marine worms. Their venoms are complex, often 
containing hundreds of different peptidic and non-peptidic 
components. The peptides are notable for their small size, 
which allows for straightforward chemical synthesis, potency, 
and receptor subtype selectivity (for general reviews, see Refs.
4-7). For instance, w-conotoxins are now the defining ligand for 
N-type (neuronal) calcium channels (8-11) and have become 
standard reagents for inhibiting neurotransmitter release. 
Similarly, p-conotoxins selectively antagonize muscle sodium 
channels (12, 13), and conantokins specifically target the N -  
methyl-D-aspartate-subtype of glutamate receptors (14-16) and 
appear to distinguish between subtypes of /V-methyl-D-aspar- 
tate receptors (17). These toxins are available in synthetic form 
and are routinely used by numerous investigators due to their 
specificity and ready availability. Nevertheless, only a small 
fraction of the hundreds of cone venoms have been analyzed.
Another series of structurally and functionally related pep­
tides from Conus venoms are the a-conotoxins. These are small, 
disulfide-rich peptides that target to nAChRs of vertebrates. 
Like the a-neurotoxins from snake venoms, previously isolated 
a-conotoxins block the nAChR at the mammalian neuromus­
cular junction, inducing paralysis. Compared to the snake tox­
ins however (approximately 80 amino acids in length), the 
a-conotoxins are much smaller (typically 12-15 amino acids in 
length) (5, 7, 18), and readily synthesized.
Seven a-conotoxins have been characterized to date from the 
venoms of three fish-eating cone snails (C. geographus, C. m a ­
gus, and C. s tria tu s). The great majority of the 500 species of 
cone snails, however, do not use their venom to paralyze fish, 
but rather to paralyze polychaete worms (>100 species), other 
molluscs (50-100 species), and various invertebrates such as 
echiuroid worms and hemichordates. Each cone species is typi­
cally very specialized, sometimes eating only one prey species. 
Since the venoms are essential for paralyzing prey, and many of 
the known prey of Conus use cholinergic transmission at their 
neuromuscular junctions, it seems likely that the venoms of 
each cone snail species will have at least one nAChR antago­
nist. Correspondingly, because of the wide diversity of different 
prey, and presumably of their respective nAChRs, the cholin­
ergic peptides found in Conus venoms are likely to include 



























the mammalian central nervous system.
As part of our broader effort to identify toxins tha t might 
serve as ligands for neuronal nAChRs in the mammalian brain, 
we are analyzing a venom from a non-fish-hunting Conus spe­
cies to explore whether it might have significantly different 
a-conotoxins. In this report, we describe the purification and 
characterization of the first o-conotoxin isolated from a ver- 
mivorous cone snail, Conus im peria lis, and demonstrate that it 
shows strikingly different biochemical and pharmacological 
properties from previously characterized a-conotoxins.
EXPERIMENTAL PROCEDURES 
Materials
Crude venom from dissected ducts of Conus imperialis was collected 
in the Philippines, lyophilized, and stored a t -70  °C until use. 0 -Mer- 
captoethanol was from Pierce Chemical Co.; dithiothreitol was from 
Boehringer Mannheim; trifluoroacetic acid (sequencing grade) was from 
Aldrich; acetonitrile (UV grade) was from Baxter (Muskegon, MI). Io- 
doacetamide and a-bungarotoxin (a-BTX) were from Sigma. a-Cono- 
toxin GI (a-CTx-GI) was synthesized as described previously (19). Tris- 
(2-carboxyethyl)phosphine (TCEP) was synthesized by the m ethod of 
Burns et al. (20).
Peptide Isolation and Sequencing
Peptide Enrichment—Crude C. imperialis venom (100 mg) was ex­
tracted with 0.1% trifluoroacetic acid a t 4 °C as previously described 
(21). The supernatan t from this extraction was transferred to a  Centri- 
con 3 Microconcentrator (Amicon, Beverly, MA) which has a 3,000 Mr 
cut-off. The Centricon Microconcentrator was centrifuged a t  7,500 rpm 
in a  Sorvall SS-34 rotor overnight a t  4 °C, and the filtrate was used for 
fu rther purification.
HPLC Purification—HPLC consisted of HPXL pumps and a Dy- 
nam ax model U V 1  detector (Rainin, Woburn, MA). For isolation of 
peptide from venom, buffer A consisted of 0.1% trifluoroacetic acid and 
buffer B was 0.1% trifluoroacetic acid, 90% acetonitrile. For purification 
and analysis of synthetic peptide, buffer A consisted of 0.1% trifluoro­
acetic acid and buffer B was 0.1% trifluoroacetic acid, 60% acetonitrile. 
Peptides were fractionated on C18 Vydac or Microsorb columns (4.6 mm 
x 25 cm, 5-pm particle size, from Rainin, Woburn, MA) (see Fig. 2).
Pyridylethylation and Purification o f Modified Peptide—Peptide 
from the final purification was stored in the  0.1% trifluoroacetic acid/ 
acetonitrile elution buffer. One hundred fifty pi of this purified peptide 
solution was combined with 30 pi of 0.1% trifluoroacetic acid, and to this 
was added 60 pi of reducing buffer (0.25 m  Na2H P 0 4, 100 m M  /3-mer- 
captoethanol, 10 m M  EDTA, and 10 m M  dithiothreitol). The reducing 
buffer was sufficient to raise the pH to a value between 7 and 8 as 
m easured by pH paper. The reaction vessel was flushed with argon and 
the reaction incubated a t 65 °C for 15 min. The solution was allowed to 
cool; 2 pi of 4-vinyl pyridine was added, and the solution was reacted for 
an additional 25 m in a t room tem perature in the dark. The solution was 
then  diluted 3-fold with 0.1% trifluoroacetic acid, and the alkylated 
peptide was purified on the Microsorb column with gradient program  2 
as described in Fig, 2.
Sequence Analysis—Sequencing was performed with Edm an chem­
istry on an Applied Biosystems model 477A Protein Sequencer a t the 
Protein/DNA Core Facility a t  the University of U tah Cancer Center.
Peptide Synthesis and Disulfide Analysis
Linear Peptide—Linear peptide was built by the m anual solid phase 
m ethod following a butoxycarbonyl/benzyl strategy, and employing a 
p-m ethylbenzhydrylam ine resin to obtain the  peptide amide. All amino 
acids were purchased from Bachem (Torrance, CA). Side-chain protec­
tion used was: S-methylbenzyl-L-cysteine, /3-O-benzyl-L-serine, L-aspar- 
tic acid /3-cyclohexyl ester, and JVe-toluenesulfonyl-L-arginine. Coupling 
reactions were carried out using TBTU (22). Prior to HF cleavage, the 
a-am ino function of the last amino acid w as deprotected by trea tm en t of 
the resin w ith trifluoroacetic acid/ethanedithiol/dichloromethane (50/5/ 
45) for 30 min. For cleavage, 3 g of peptidyl-resin was trea ted  with 
liquid H F a t 0 °C in  the presence of anisole (10%) and dimethylsulfide 
(3%) for 75 min. This procedure sim ultaneously cleaved peptide from 
the resin and deprotected all side chains.
Peptide Cyclization—After removal of H F under vacuum, th e  linear 
peptide and resin were washed with e ther and the m ixture (peptide + 
resin) was introduced into 3500 ml of isopropanol/H20  (50/50) and 
gently stirred. The pH (checked by pH paper) was m aintained a t 8 -9  by 
adding diisopropylethylamine during th e  a ir oxidation reaction. Prog­
ress of the  oxidation was monitored by HPLC and th e  Ellm an test (23) 
and was judged to be complete after 5 days. The solution was filtered to 
remove the  resin, the pH was adjusted to 5 by the  addition of acetic acid, 
and isopropanol was evaporated. After dilution with water, the peptide 
was purified by preparative reversed-phase HPLC on a Vydac C 18 col­
umn, using a gradient of acetonitrile in 0.1% trifluoroacetic acid. Its 
identity w ith n a tu ra l peptide was verified by co-elution experiments on 
HPLC and capillary zone electrophoresis (CZE), by m ass spectrometry, 
and by disulfide “fingerprinting” (below).
Disulfide Analysis—The partial reduction strategy of Gray (24) was 
used. Twenty nanomoles of synthetic peptide, as eluted from HPLC, was 
incubated a t room tem perature w ith 10 mM TCEP in 0.1 m citrate, pH 3. 
After 2-5 min the reaction m ixture was diluted with 0.1% trifluoroace­
tic acid to decrease acetonitrile concentration and imm ediately injected 
onto the HPLC column. Peptide fractions, as identified by UV absorb­
ance were collected manually into 1.5-ml polypropylene centrifuge 
tubes. Monocyclic interm ediates were alkylated with 100 mg of iodoac- 
etam ide using the rapid alkylation method (24). Labeled peptides were 
subm itted to sequence analysis to determ ine the locations of S-carbox- 
amidomethyl-L-cysteine residues, and hence the disulfide connectivity.
Disulfide Fingerprinting—Approximately 200 pmol of peptide in 50 
pi of HPLC eluent were mixed w ith 50 pi TCEP (20 m M  in 0.2 m citrate, 
pH 3). After brief incubation a t room tem perature, the m ixtures were 
analyzed by HPLC, to compare product distributions of na tura l and 
synthetic m aterials.
Electrophysiology
Intracellular Recording from R. pipiens Muscle Fibers—Freshly dis­
sected cutaneus pectoris muscle was pinned on a  thinly Sylgard-coated 
(<0.5 mm) 25-mm diam eter #1  coverslip and placed in an ~1.2-ml 
chamber which was perfused with Ringer’s solution consisting of 10 mM 
Na HEPES, pH 7.2, 111 mM NaCl, 1.8 mM CaCl2, and 2 mM KC1. In tra ­
cellular recording and iontophoretic application of carbamylcholine 
were performed under visual control as described previously (25).
Iontophoretic Application of Carbamylcholine (CCh) and Focal Toxin 
Application—The tip of the iontophoretic CCh pipette (containing 1 m 
CCh) was placed near a  neurom uscular junction and CCh was ejected 
w ith current pulses (~50 nA, 5-ms duration) applied a t a frequency of 
0.1 Hz. The response to each pulse was recorded, and the peaks of the 
response am plitudes were plotted (see Fig. 5). A puffer-pipette was used 
to apply peptide toxin as previously described (26). Specifically here, a 
glass m icropipette (tip inner diameter, 6 pm) was filled with 50 pM 
ri-CTx-lml in Ringer’s. I ts  tip was placed about 50 pm away from the  tip 
of the CCh pipette a t the neurom uscular synapse, and peptide was 
ejected by application of puffs of pressure (2 p.s.i., 50-ms duration) to 
the pipette. The puffer pipette was placed a t a  fairly large distance (50 
pm) to insure th a t 1) the toxin diffused to a postsynaptic area which 
encompassed the area affected by iontophoresed CCh, and 2) the puff of 
toxin did not mechanically disturb the position of the  tip of the CCh 
pipette relative to the postsynaptic membrane. D ata were acquired on 
a M acintosh computer with an A/D board (Lab NB, National In stru ­
ments, A ustin Texas) and our own virtual instrum ents (constructed 
w ith the graphical programming language LabVIEW also from N a­
tional Instrum ents).
Toxin Effect on MEPPs—Spontaneous m iniature endplate potentials 
(MEPPs) were recorded intracellularly  as above. To facilitate recording 
of MEPPs, their amplitudes and durations were increased by irrevers­
ibly blocking acetylcholinesterase in the preparation by exposing the 
muscle to 1 mM methanesulfonyl fluoride (Eastm an Chemicals, Roch­
ester, NY) in R inger’s for 1 h  (cf. Ref. 27). Spontaneous MEPPs were 
acquired on a Macintosh as described above with a v irtual instrum ent 
which captured all transien ts w ith am plitudes exceeding 0.4 mV. The 
recordings of individual transien ts were visually inspected off-line, and 
all those which did not have profiles characteristic of MEPPs were 
culled out.
Extracellular Recording in R. pipiens—Extracellular recording of 
postsynaptic responses to motor nerve stim ulation in  a cutaneus pec­
toris muscle from R. pipiens was performed essentially as described 
previously (28). Specifically, the muscle was placed in a  Sylgard record­
ing cham ber (15 mm long x 1 mm wide x 2.5 mm deep); the motor nerve 
was passed through a petroleum  jelly (Vaseline®) gap into an adjacent 
well containing embedded P t stim ulating electrodes. The muscle was 
bathed with frog R inger’s solution supplemented with 0.25 mg/ml ly- 
sozyme to minimize possible nonspecific absorption of the conotoxins. 
a-Conotoxins were dissolved in normal frog Ringer's containing 0.25 
mg/ml lysozyme. Toxins were applied to the preparation and a plastic 
coverslip was placed over the recording cham ber to minimize buffer 























every 30-60 s with a  supram axim al 0.1-ms pulse. The resulting action 
potential in the muscle was recorded extracellularly by m eans of Pt 
electrodes (embedded in the Sylgard chamber) connected to a  Grass 
amplifier (model P15B). D ata was captured by computer as described 
above.
Extracellular Recording from Electrocytes in Eigenmannia—Fish 
were anesthetized by chilling in ice-cold w ater and decapitated, and the 
distal approximately 4 cm of the tail was removed and fu rther prepared 
as follows: sta rting  a t the  anterior end of the piece of tail, the  entire skin 
surrounding the tail was peeled away from the immediately underlying 
tissue (consisting of muscle/electrocytes). The tissue surrounding the 
anterior end of the spinal column was removed over a 2-4-mm length 
approximately 14 mm from the  distal end of the tail to yield a “spinal 
stum p.” The posterior tip  (—14 mm) of the tail was severed away, and 
the preparation was placed in a  recording cham ber constructed of Syl­
gard (15 mm long x 2 mm wide x 2 mm deep) filled with Hickman’s 
solution (110 m M  NaCl, 2 m M  KCI, 3 m M  CaCl2, 2 m M  M gS04, 1 m M  
N aH C 03, 1 mM N a2H2PO,„ pH 7.2) plus 0.25 mg/ml lysozyme. The 
spinal stum p was placed across a petroleum  jelly gap and electrically 
stim ulated (via P t electrodes on e ither side of the  gap) every 30-60 s 
with a  supram axim al 0.1-ms pulse. The resulting  action potential from 
the electrocytes or electric organ discharge (EOD) was recorded extra­
cellularly with P t electrodes embedded in the chamber. Recording elec­
tronics were as described for the  R. pipiens preparation above. Toxins 
were dissolved in the Hickman’s solution plus lysozyme buffer and 
applied directly to the bath. Recordings were taken  for 20-25 min.
Bioassay—Biological activity of peptide fractions was tested by in- 
traperitoneal or in tracranial injection into young mice as described 
previously (29). Twenty-pl volumes were injected intracerebrally, and 
50-pl volumes were injected intraperitoneally, using insulin syringes 
with 29-gauge needles. In tracerebral-ventricular injections were made 
in Sprague-Dawley rats. R ats (450-550 g) were deeply anesthetized 
with pentobarbital and placed in a Stoelting stereotaxic apparatus. The 
scalp was incised, and a 1-mm hole was drilled in the skull a t the 
stereotaxic coordinates 0.92 mm posterior to bregma and 1.4 mm lateral 
to midline. A 25-gauge stainless steel cannula (outer diameter, 0.02, 
inner diameter, 0.01, preset in a 1/8 nylon set screw, was inserted to a 
depth of 3.5 mm. A “copper crown” m ade of 0.5 in d iam eter x 1/4 in 
length copper pipe was placed around the cannula to prevent m echani­
cal dislodgment. C annula and crown were secured with dental cement. 
Animals were allowed to recover for a t least 3 days prior to use. 
Three-pl injections were made with a  10-ul Ham ilton syringe and 33- 
gauge b lun t tip needle. In some cases, position of the cannula in the 
lateral ventricle was confirmed histologically.
RESULTS
Isolation o f a-Conotoxin Im l (a-CTx-Iml)—Our long term 
goal is to identify a-conotoxin-type peptides from non-fish- 
hunting Conus venoms, with an emphasis on those which 
might act on subtypes of mammalian neuronal nicotinic ace­
tylcholine receptors. The initial venom examined, and the sub­
ject of this report, was that of the imperial cone, Conus im pe­
rialism obtained by dissecting venom ducts from specimens 
mostly collected off Cape Bolinao, Luzon Island, Philippines. 
This species hunts the polychaete worm, Eurythoe com planata. 
Photographs of C. im perialis  and other cone shells are shown in 
Fig. 1.
Several guidelines were used to identify candidate peptides 
with the desired characteristics. Since these were likely to be 
related structurally to the a-conotoxins, which are the smallest 
of the major toxins in fish-hunting cone venoms, we first ex­
amined the smaller peptides found in C. im perialis  venom. The 
first step in purification involved filtration through a mem­
brane with a cut-off of 3000 daltons (the Centricon 3 microcon­
centrator).
The filtrate was then purified using a C18 reverse phase 
column (see Fig. 2A). The UV absorbance pattern is relatively 
simple, since larger peptides and polypeptides were retained by 
the filtration procedure. Peptides targeted for further purifica­
tion were those that were biologically active upon intracranial 
injection into mice. This has been a reliable method for isolat­
ing central nervous system-targeted ligands. The fraction indi-
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Fig. 1. Cone snails from which a-conotoxins have been iso­
lated. Top panel, the  imperial cone snail, Conus imperialis. Bottom 
panel, three  fish-eating cone snails: C. magus (top left), C. striatus (top 
right), and C. geographus (bottom). Bar = 1 cm in both panels.
cated by an arrow  in Fig. 2A induced seizures upon intracranial 
injection.
This fraction was rechromatographed with a much shallower 
gradient of acetonitrile (Fig. 2B  ). The earlier-eluting peptide 
elicited scratching upon intracranial injection, and proved to be 
Lys-conopressin G (30). The major component was further pu­
rified on a Microsorb column (Fig. 2C) and biochemically char­
acterized.
Biochem ical Characterization o f a-Conotoxin Im l—The pep­
tide purified as described above was reduced, alkylated and 
sequenced as described under “Experimental Procedures.” The 
results of the sequence analysis are shown in Table I; these 
were verified with a second independent analysis, which gave 
similar results. The peptide has only 12 amino acids, including 
4 Cys residues. Fast atom bombardment mass spectrometry 
indicated tha t Cys residues are present as disulfides and that 
the C terminus is amidated (monoisotopic MH+: calculated, 
1351.48; found, 1351.5).
Synthetic peptide prepared as described in Methods co­
eluted with natural peptide on HPLC and CZE (Fig. 3) and had 
the correct molecular mass (monoisotopic MH+: calculated, 
1351.48; found, 1351.4). Partial reduction by TCEP of 200 pmol 
of natural and synthetic peptides gave essentially identical 
product profiles on HPLC (Fig. 4). This is a sensitive test of 
identity of disulfide bridging. The two monocyclic peptides R1A 
and RIB were isolated from a larger scale reduction of syn­
thetic material and alkylated with iodoacetamide. Sequence 
analysis showed that R1A was alkylated exclusively at Cys-2 
and Cys-8, while RIB was alkylated exclusively at Cys-3 and 
Cys-12. Thus the disulfide bridging pattern is [2-8; 3-12], simi­
lar to that in a-conotoxin GI: [2-7; 3-13], where brackets en­



























Fig. 2. Purification of a-CTx-Iml 
from C. im peria lis  venom. Buffer A =
0.1% trifluoroacetic acid; buffer B = 0.1% _
trifluoroacetic acid, 90% acetonitrile. ^ 0
Panel A, venom fraction from u ltra filtra ­
tion (see text) was applied to a C18 Vydac — ^  80 
column. G radient program  1 was 0-45%
B/40 min, followed by 45-100% B/15 min. ^
Panel B, m aterial eluting a t 23.9 m in (ar- CM 
row in panel A ) was rerun  on the sam e ^  
column with gradient program  2 (2- 10%
B/3 min; 10—25% B/57 min). Panel C, m a­
terial eluting a t 36.4 m in (arrow in panel 
B) was rerun  on the  Microsorb column 
with gradient program  2 to obtain the fi­
nal purified product. The solid line is the 
absorbance a t 214 nm, and the dashed 
line is the gradient of acetonitrile.
Table I
Sequence analysis o f a-conotoxin Im l from C. imperialis 
PTH, phenylthiohydantoin-derivative.
m
I  60 
8





Step Assigned residue Yield
1 Gly













20 24 28 41
T im e (min)
Thus, although most of the sequence is quite divergent, and 
the number of amino acids within the disulfide loops is differ­
ent from those in previously isolated peptides, the disulfide 
arrangement clearly places the peptide in the a-conotoxin 
class. As will be described below, the peptide does indeed target 
to nicotinic acetylcholine receptors. We have, therefore, named 
this peptide a-conotoxin Iml (a-CTx-Iml), using the nomencla­
ture for conotoxins previously proposed.
Biological A c tiv ity  in  Vivo o f  a-Conotoxin I m l—An assess­
ment of the biological activity of a-CTx-Iml by intracranial 
injection in young mice (6-10 g weight) showed natural and 
synthetic peptides to be indistinguishable. At low doses (0.5-2 
nmol), the symptoms included flattening of ears, back arching, 
slight spreading of hindlegs, rapid walking, and climbing the 
sides of the cage, as well as hypersensitivity to tactile stimuli. 
When a puff of air was blown onto the fur, the test mice would 
jump much higher than saline-injected controls. At intermedi­
ate doses (3-5 nmol) symptoms were more pronounced, and a 
coarse tremor and complex generalized seizures were also ob­
served. At 6-10 nmol, the wide-based gait was so pronounced 
tha t the legs were sometimes completely outstretched. In ad­
dition, most mice died following the complex seizures. In con­
trast, intraperitoneal injection of up to 10 nmol of a-conotoxin 
Iml did not elicit any notable symptoms. At 20 nmol, some 
suggestion of ear flattening and hypersensitivity to tactile 
stimuli was observed, which may be due to a small fraction of 
peptide crossing the blood-brain barrier and entering the cen­
tral nervous system (w-conotoxin-GVIA is known to cross the 
blood-brain barrier in small amounts).
The effect of intracerebral-ventricular injections of synthetic
a-conotoxins into Sprague-Dawley rats was also assessed. Fol­
lowing injection of 5-10 nmol of a-CTx-Iml, crouching, a coarse 
tremor and wide-based gait were observed, while following 20­
nmol injections complex general seizures were induced lasting 
from 10-30 s, followed by 2-4-min interictal periods. After sev­
eral seizures, one of two animals died. In contrast, intracere­
bral-ventricular injection of 40 nmol of the previously charac­
terized a-conotoxin, GI (a-CTx-GI), elicited no effects in two 
rats tested. The two rats tha t showed no effect from a-CTx-GI 
were injected intracerebral-ventricularly the next day with 15 
nmol of a-CTx-Iml, which produced the expected symptoms. 
Intracerebral-ventricular injection of 12 nmol of a-bungaro­
toxin (a-BTX) produced tremor and a single seizure, while in­
jection of 20 nmol induced repetitive seizures and death.
As shown in Table II, the effects of a-conotoxins in mamma­
lian systems are more restricted than those of a-BTX. In mam­
mals, a-BTX has both peripheral and central nervous system 
effects, a-CTx-GI has peripheral effects and is inactive upon 
intracerebral-ventricular injection, while the new peptide, 
a-C Tx-Im l, shows the reciprocal profile with only central ef­
fects and no paralytic symptoms upon intraperitoneal injection 
at the doses tested.
A ctiv ity  o f  a-Conotoxin I m l  a t N eurom uscu lar Ju n c tio n s— 
The cysteine framework and biological activity of a-CTx-Iml 
strongly suggested that it is a ligand for an nAChR. To test this 
hypothesis electrophysiologically, experiments were performed 
on th e  frog  neuromuscular junction. Application of toxin from a 
pipette containing 50 pM toxin blocked depolarizations induced 
by iontophoretically applied carbamylcholine (Fig. 5). Fig. 6 
shows th a t bath-applied peptide (0.2 jim) blocks MEPPs. At this 
concentration of toxin, the mean MEPP amplitude was reduced 
to 29% of the control value. There was no effect on MEPP 
frequency indicating that the peptide has no apparent presyn- 
aptic effects. When higher concentrations of toxin were used 
(e.g. 50 jim applied through a puffer pipette), complete but 
reversible block of MEPPs occurred (results not shown). These 
results indicate that the toxin blocks the postsynaptic nAChR.
Since a-CTx-Iml was isolated from a worm-hunting cone, it 
was of interest to compare its phylogenetic activity profile to 
that of a-CTx-GI (isolated from a fish-hunter). Extracellular 
recording of synaptically evoked action potentials at the frog 
neuromuscular junction and electrocytes from the weakly elec­
tric fish E igenm ann ia  was used for this purpose.
As shown in Table III, the IC50 of a-CTx-Iml was 250-500 nM 
in frog. Under the same conditions, a-CTx-GI caused inhibition 
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Fig. 3. Comparison of natural and 
synthetic o-conotoxin Iml by capil­
lary zone electrophoresis (CZE). Anal­
ysis was performed a t 30 °C on a Beck­
m an P/ACE System 2050, monitored at 
214 nm, with SpectraPhysics Chrom Jet 
SP4400 integrator. Peptides were applied 
by pressure  injection onto fused silica cap­
illaries from Beckman (50 cm x 75 pm). 
Buffer was 100 mM H 3P 0 4 adjusted to pH 
2.5 by addition of 2 m NaOH. Analysis was 





Fig. 4. Disulfide fingerprinting of synthetic (panel A) and 
natural (panel B) o-conotoxin Iml. Partia l reduction was carried 
out by incubating 200 pmol of peptide w ith 10 pm TCEP in 100 m l of 0.1 
M sodium citrate, pH  3, for 4 m in a t 25 "C. Samples were analyzed by 
reverse-phase HPLC as described under “Experim ental Procedures.” 
G radient was 15-35% B in 40 min; segm ent depicted in each case is 
from 27-35% B. Peptides corresponding to the absorbance peaks in 
panel A  were identified as follows; N, unreduced; R2, fully reduced; R1A 
and R IB , monocyclic interm ediates.
Table II
Comparison o f biological effects in mammals 
Intraperitoneal injections of toxins were done in mice and in tracere­
bral-ventricular injections were m ade stereotactically in  ra ts. a-CTx- 
Im l produces complex behavioral effects including seizures when in ­
jected centrally bu t does not cause paralysis when injected peripherally. 
a-CTx-GI produces the  opposite result: no effect on intracerebral-ven­
tricu lar injection and  paralysis and death  with peripheral injection. 

















toxins were reversible with 30 min of washing (results not 
shown). Thus, a-CTx-Iml is significantly more potent than 
a-CTx-GI at the frog neuromuscular junction.
However, the reverse order of potency was found when these 
peptides were tested on electrocytes from E igenm annia . a-CTx- 
Iml had an IC50 of 25-50 j im , while a-CTx-GI had an IC50 of
Time (m sec)
F ig . 5. Panel A, tim e course of block by a-CTx-Iml. CCh was ionto- 
phoretically applied every 10 g throughout the experiment. At tim e zero, 
a puff of a-CTx-Iml was delivered from a pipette filled with 50 pm 
peptide. The response to CCh imm ediately declined, then gradually 
recovered, a , ju s t  before toxin puff; b, immediately after toxin puff; c, 
after recovery. Panel B, sam ple responses to CCh before, during, and 
after toxin application. Two responses a t each tim e point are shown 
(times correspond to points indicated by a, b, and c in panel A). The 
fixed, 5-ms iontophoretic pulse of CCh was applied 10 ms into the trace 
(note rectangular artifact with fixed am plitude and duration from ms 10 
to 15). The application of toxin totally blocked the CCh response (6 ). The 
response recovered completely w hen toxin had diffused away. Note th a t 
traces a (before toxin) and c (after recovery) are virtually superimpos- 
able. The resting  potential rem ained essentially constant throughout 
th is period, indicating th a t the toxin had no untoward effects on the 


























F ig . 6. a-CTx-Iml reduces M EPP am plitude  b u t n o t frequency.
Shown are sample traces of M EPPs before (largest four responses) and 
during (sm allest four responses) exposure to 200 nM toxin. Mean am ­
plitude ± S.D. of MEPPs was 2.37 ± 0.97 mV (control, n = 59) and 0.69 
± 0.26 (toxin present, n = 67). The frequency of MEPPs was essentially 
unaffected by toxin; M EPP frequency was 6.8/m in in control R inger’s 
and 6.3/min when toxin was in the  bath. This slightly lower apparent 
M EPP frequency in the  presence of toxin is thought to result from an 
increased frequency of unrecorded MEPPs, whose amplitudes were too 
low to trigger capture by the computer.
Table III
Relative potencies of a-conotoxin Im l and a-conotoxin GI 
The potency of a-CTx-Iml and a-CTx-GI was compared electrophysi- 
ologically in fish and frog. The concentration (in jim) of toxin required to 
inhibit the synaptically m ediated action potential by a t least 50% was 
determined. ar-CTx-Iml is 100-fold more potent in frog th an  in fish. In 





50-100 n M . Thus, a-CTx-GI is approximately 500 times more 
potent than a-CTx-Iml in blocking a teleost neuromuscular 
preparation (see Table III), while in the amphibian system, 
a-CTx-Iml is 8-fold more potent than a-CTx-GI.
DISCUSSION
The venom of Conus im peria lis is a complex mixture of bio­
logically active agents. We previously reported the isolation of 
a vasopressin analog (30) and serotonin (21) from this venom. 
This report describes the first paralytic peptide characterized 
from C. im perialis, the novel nAChR antagonist, a-conotoxin 
Iml. Numerous other peptides are present which remain to be 
fully characterized. Since ACh is the neurotransmitter at an­
nelid neuromuscular junctions, it is reasonable to suppose that 
a peptide targeted to the nAChR would be a major component 
of the venom of a vermivorous species such as C. im perialis. On 
the other hand, since the invertebrate prey of C. im perialis  are 
quite distinct phylogenetically from the fish prey of previously 
characterized cones (e.g. C. geographus), it is not surprising 
tha t their respective a-conotoxins would differ both structur­
ally and functionally.
Structural R elationships—Previously characterized a-cono­
toxins can be divided into two structural classes. These two 
classes have distinctive sequence features, particularly in the 
second disulfide loop (see Table IV) where the presence of a 
proline residue in a-CTx-SI and a-CTx-SII is a diagnostic fea­
ture. In other respects however, all previously characterized 
a-conotoxins have a core sequence CC(N/H)PACGXX(Y/F)XC in 
common.
Table IV 
a-Conotoxin sequence comparison 
a-Conotoxins from several species of Conus are shown. C. geographus, 
C. magus, and C. striatus are fish-eaters. The sequence of a-CTx-Im-I 
from the worm-eating C. imperialis differs from the others not only in 
the num ber of amino acids between cysteines (4,3) bu t also in overall 
amino acid composition. Note th a t disulfide bond patte rn  has not been 
definitively determined for GII, SIA, or SII bu t is assum ed to be con­
served. A single or double asterisk  indicates th a t the a-carboxyl group 
is known to be either am idated or the  free acid, respectively.









n  i i
G CCSDPRCAW RC*
n-----1 i
E CCN PA CG RH Y SC*
ECCNPACGRHY SCGK *
n — i i
EC C H PA C G K H FSC *
n — i i
GRCCHPA CG KN Y SC*
I
YCCHPA CGK N FDC*
IC C N PA C G P K Y S C *











6 Gray e t al„ 1981 (31).
c M cIntosh et al., 1982 (18).
d Gray et al., 1983 (32).
‘ Myers et al., 1991 (33).
^Zafaralla et al., 1988 (34).
* Ramilo et al., 1992 (35).
Clearly, a-CTx-Iml does not fit the consensus sequence 
above, and is much more divergent than the two previously 
characterized groups of a-conotoxins are from each other. The 
first disulfide loop contains four amino acids rather than three, 
and lacks the characteristic (N/H)PA sequence of all other 
a-conotoxins. Also, in contrast to the 5 amino acids in the sec­
ond loop of other a-conotoxins, Iml has only 3. Despite the 
divergence in sequence and size of the disulfide loops, the link­
age of the disulfides [2-8; 3-12] is exactly analogous to that in 
a-conotoxin GI [2-7; 3-13]. Further studies on disulfide iso­
mers and folding of Iml will be reported elsewhere.2 It will be of 
great interest to compare the three dimensional structure of 
the different groups of a-conotoxins. The solution structures of 
a-CTx-GI and a-CTx-SI have been determined by NMR spec­
troscopy (36).3 NMR studies of a-CTx-Iml are currently in 
progress.
Phylogenetic Specificity for Muscle nAChRs—In view of the 
structural divergence, it is not surprising that a-CTx-Iml has a 
unique functional profile. Based on their activity in phyloge­
netically distinct organisms, the two previously characterized 
groups of a-conotoxins have distinctive specificities. The first 
group (typified by a-CTx-GI and a-CTx-MI) are active in all 
vertebrates tested including mammals, while the second group 
(typified by a-CTx-SI and a-CTx-SII), are highly potent in tel- 
eosts, but have little activity in mammals.
We have used the cutaneus pectoris preparation from R. 
pip iens  to demonstrate that a-CTx-Iml is a potent inhibitor of
2 W. R. Gray, E. Mahe, J . M. McIntosh, B. M. Olivera, and J. E. Rivier, 
m anuscript in preparation.
3 D. J . Christensen, C. D. Poulter, R. A. Myers, and B. M. Olivera, 
m anuscript in  preparation.

























the nAChR in frog neuromuscular junction. In contrast, how­
ever, a-CTx-Iml is two orders of magnitude less potent in block­
ing the synaptically mediated action potential in electrocytes 
from weakly electric fish and is inactive peripherally when 
injected intraperitoneally into mice. Thus, in accord with its 
very distinct amino acid sequence, the phylogenetic activity 
profile of a-CTx-Iml places this peptide into a novel third cat­
egory.
M a m m a lia n  nA C hR  Specificity—Another unique feature of 
a-conotoxin Iml is that the peptide is active in mammalian 
central nervous system, but not at the neuromuscular junction. 
In this regard, it is instructive to compare and contrast the 
activities of three cholinergic polypeptide ligands, a-BTX, 
a-CTx-GI, and a-CTx-Iml. All three toxins block cholinergic 
transmission at the frog neuromuscular junction. In mamma­
lian systems {e.g. rodent), however, the three ligands have dif­
ferent activity profiles a t the doses tested. a-BTX causes sei­
zures upon intracerebral-ventricular injection and paralysis 
upon intraperitoneal injection. a-CTx-GI induces no symptoms 
upon intracerebral-ventricular injection and causes paralysis 
upon intraperitoneal injection. a-CTx-Iml injected intracere- 
bral-ventricularly causes seizures a t doses comparable to 
a-BTX, but upon intraperitoneal injection shows no paralytic 
activity even at doses 100 x (2 nmol/g mouse) greater than the 
LD50 (18.75 pmol/g mouse) for a-BTX.
a-BTX has a t least two different mammalian nAChR targets, 
the peripheral neuromuscular receptor, and a central nervous 
system nAChR subtype(s), which recent work suggests includes 
a7-containing nAChR complexes (2). a-CTx-GI appears to se­
lectively block the neuromuscular receptor {37, 38), and has no 
activity in the central nervous system. In contrast, a-CTx-Iml 
does not inhibit the mammalian neuromuscular nAChR, but is 
centrally active. Whether the neuronal receptor subtypes af­
fected by a-CTx-Iml correspond precisely to the central nervous 
system targets of a-BTX remains to be investigated. Although 
a-CTx-Iml blocks the nAChR at frog neuromuscular junction, it 
is conceivable that the central nervous system target in mam­
mals is not a neuronal nAChR but some other receptor. How­
ever, preliminary evidence from X enopus  oocyte expression 
studies indicates tha t a-CTx-Iml targets a specific neuronal 
nAChR.4
Neuronal nAChRs appear important in human cognition (39) 
and nicotinic cholinergic transmission has been implicated in 
neuropsychiatric disorders including schizophrenia (40), move­
ment disorders (41, 42) and Parkinson’s disease (43, 44). De­
spite their importance, there are relatively few ligands to dis­
tinguish between the multiple neuronal nAChRs. C. im peria lis  
represents only one of many worm-eating cone snails. A pre­
liminary genetic analysis of two additional non-fish-hunting 
species has revealed the presence of several a-conotoxin-like 
sequences.5 These sequences are as different from a-CTx-Iml 
as a-CTx-Iml is from the peptides produced by fish-hunting 
cones. Thus, because of the variability of a-conotoxins in non- 
piscivorous cone snail venoms, such venoms constitute a re­
source of great potential for the isolation of novel neuronal 
nAChR-targeted peptides.
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